Literature DB >> 25560712

D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.

Clive Kearon, Frederick A Spencer, Denis O'Keeffe, Sameer Parpia, Sam Schulman, Trevor Baglin, Scott M Stevens, Scott Kaatz, Kenneth A Bauer, James D Douketis, Steven R Lentz, Craig M Kessler, Stephan Moll, Jean M Connors, Jeffrey S Ginsberg, Luciana Spadafora, Jim A Julian.   

Abstract

BACKGROUND: Normal D-dimer levels after withdrawal of anticoagulant therapy are associated with a reduced risk for recurrence in patients with unprovoked venous thromboembolism (VTE) and may justify stopping treatment.
OBJECTIVE: To determine whether patients with a first unprovoked VTE and negative D-dimer test result who stop anticoagulant therapy have a low risk for recurrence.
DESIGN: Prospective management study with blinded outcome assessment. (ClinicalTrials.gov: NCT00720915).
SETTING: 13 university-affiliated clinical centers. PATIENTS: 410 adults aged 75 years or younger with a first unprovoked proximal deep venous thrombosis or pulmonary embolism who had completed 3 to 7 months of anticoagulant therapy. INTERVENTION: Anticoagulant therapy was stopped if D-dimer test results were negative and was not restarted if results were still negative after 1 month. MEASUREMENTS: Recurrent VTE during an average follow-up of 2.2 years.
RESULTS: In 319 patients (78%) who had 2 negative D-dimer results and did not restart anticoagulant therapy, rates of recurrent VTE were 6.7% (95% CI, 4.8% to 9.0%) per patient-year overall (42 of 319), 9.7% (CI, 6.7% to 13.7%) per patient-year in men (33 of 180), 5.4% (CI, 2.5% to 10.2%) per patient-year in women with VTE not associated with estrogen therapy (9 of 81), and 0.0% (CI, 0.0% to 3.0%) per patient-year in women with VTE associated with estrogen therapy (0 of 58) (P = 0.001 for the 3-group comparison). LIMITATIONS: Imprecision in female subgroups. Results may not be generalizable to different D-dimer assays from the one used in the study.
CONCLUSION: The risk for recurrence in patients with a first unprovoked VTE who have negative D-dimer results is not low enough to justify stopping anticoagulant therapy in men but may be low enough to justify stopping therapy in women. PRIMARY FUNDING SOURCE: Canadian Institutes of Health Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25560712     DOI: 10.7326/M14-1275

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  28 in total

Review 1.  Who should get long-term anticoagulant therapy for venous thromboembolism and with what?

Authors:  Marc Alan Rodger; Gregoire Le Gal
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Bevacizumab Plus Direct Oral Anticoagulant Therapy in Ovarian Cancer Patients with Distal Deep Vein Thrombosis.

Authors:  Shinichi Komiyama; Masaru Nagashima; Tomoko Taniguchi; Takayuki Rikitake; Mineto Morita
Journal:  Clin Drug Investig       Date:  2019-04       Impact factor: 2.859

Review 3.  Who should get long-term anticoagulant therapy for venous thromboembolism and with what?

Authors:  Marc Alan Rodger; Gregoire Le Gal
Journal:  Blood Adv       Date:  2018-11-13

4.  D-dimer testing to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: follow the rules!

Authors:  Alessia Abenante; Francesca Zuretti; Cristina Dedionigi; Flavio Tangianu; Francesco Dentali
Journal:  Intern Emerg Med       Date:  2019-12-07       Impact factor: 3.397

Review 5.  [Pulmonary embolism and direct oral anticoagulants].

Authors:  Horst Olschewski
Journal:  Wien Med Wochenschr       Date:  2016-03-16

Review 6.  Guidance for the treatment of deep vein thrombosis and pulmonary embolism.

Authors:  Michael B Streiff; Giancarlo Agnelli; Jean M Connors; Mark Crowther; Sabine Eichinger; Renato Lopes; Robert D McBane; Stephan Moll; Jack Ansell
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

7.  Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism.

Authors:  Clive Kearon; Sameer Parpia; Frederick A Spencer; Trevor Baglin; Scott M Stevens; Kenneth A Bauer; Steven R Lentz; Craig M Kessler; James D Douketis; Stephan Moll; Scott Kaatz; Sam Schulman; Jean M Connors; Jeffrey S Ginsberg; Luciana Spadafora; Vinai Bhagirath; Patricia C Liaw; Jeffrey I Weitz; Jim A Julian
Journal:  Blood       Date:  2018-02-28       Impact factor: 22.113

8.  Retrospective review of D-dimer testing for venous thrombosis recurrence risk stratification: is this a useful test in the real world?

Authors:  Julie Wang; Mark Tacey; Prahlad Ho
Journal:  J Thromb Thrombolysis       Date:  2020-05       Impact factor: 2.300

9.  High incidence of venous thromboembolism recurrence in patients with sickle cell disease.

Authors:  Ann Brunson; Theresa Keegan; Anjlee Mahajan; Richard White; Ted Wun
Journal:  Am J Hematol       Date:  2019-06-12       Impact factor: 10.047

Review 10.  Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?

Authors:  Fionnuala Ní Áinle; Barry Kevane
Journal:  Blood Adv       Date:  2020-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.